← Back to guidelines
Cardiology451 papers

Primary non-small cell lung cancer

Last edited: 4/15/2026

Overview

Primary non-small cell lung cancer (NSCLC) is a malignant neoplasm arising from lung tissue, distinct from small cell lung cancer, characterized by diverse histological subtypes including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma 1.

Diagnosis

  • Imaging studies (CT, PET scans) for tumor localization and staging 1.
  • Tissue biopsy (bronchoscopy, needle aspiration) for histopathological confirmation 1.
  • Assessment of biomarkers (EGFR, ALK, ROS1) for targeted therapy eligibility 1.
  • Management

  • First-line treatments:
  • - Systemic therapy (platinum-based chemotherapy, targeted agents like EGFR inhibitors, ALK inhibitors) based on histology and biomarker status 1. - Surgical resection (lobectomy, pneumonectomy) for early-stage disease 1.
  • Adjunctive treatments:
  • - Radiation therapy for unresectable tumors or post-surgery adjuvant setting 1. - Symptomatic management with bisphosphonates, NSAIDs, and octreotide for complications like hypertrophic osteoarthropathy 1.

    Special Populations

  • Comorbidities: Management strategies may need adjustment in patients with comorbidities; specific dosing and treatment modalities should be individualized 1.
  • No specific data on pediatrics, pregnancy, or elderly populations provided in the abstracts 1.
  • Key Recommendations

  • Primary treatment modalities (surgical resection, chemotherapy, targeted therapy) should be tailored based on tumor stage and biomarker status (Evidence: Moderate 1).
  • Symptomatic treatments such as bisphosphonates and NSAIDs are recommended for managing complications like hypertrophic osteoarthropathy, though evidence is primarily from case reports and series (Evidence: Weak 1).
  • Further research is needed to elucidate optimal management strategies for hypertrophic osteoarthropathy secondary to NSCLC due to lack of high-quality clinical trials (Evidence: Expert opinion 1).
  • References

    1 Nguyen S, Hojjati M. Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy. Clinical rheumatology 2011. link 2 Lukacin R, Matern U, Junghanns KT, Heskamp ML, Britsch L, Forkmann G et al.. Purification and antigenicity of flavone synthase I from irradiated parsley cells. Archives of biochemistry and biophysics 2001. link

    Original source

    1. [1]
    2. [2]
      Purification and antigenicity of flavone synthase I from irradiated parsley cells.Lukacin R, Matern U, Junghanns KT, Heskamp ML, Britsch L, Forkmann G et al. Archives of biochemistry and biophysics (2001)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG